Teva Pharmaceutical Industries Ltd.

Director's Dealing • Mar 2, 2023

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287

Estimated average burden hours per response... 0.5

Check this box if no

longer subject to Section 16. Form 4 or

Instruction 1(b).

Form 5 obligations may continue. See STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person Kalif Eliyahu Sharon			2. Issuer Name and Ticker or Trading Symbol Teva Pharmaceutical Industries Ltd. [TEVA]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _ Director _ 10% Owner
(Last) 124 Dvora HaNevi'a St.,	(First) C/O Teva Pharmaceutical Industries Ltd.	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 02/28/2023	Officer (give title below)____ Other (specify below) X EVP, Chief Financial Officer
(Street) Tel Aviv L3 6944020 (City) (State) (Zip)			4. If Amendment, Date Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person ____ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)	2. Transaction 2A. Deemed 3. Transaction Date Execution Date, if Code (Month/Day/Year) any (Instr. 8)				4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form:	7. Nature of Indirect Beneficial
		(Month/Day/Year)	Code	V	Amount	(A) or (D)	Price	(Instr. 3 and 4)	Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)
(1) Ordinary Shares	02/28/2023		M		18,430	A	(2)	34,435	D
(1) Ordinary Shares	02/28/2023		M		44,953	A	(2)	79,388	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction 3A. Deemed 4. 5. Number of Date Execution Date, if Transaction Derivative (Month/Day/Year) any Code Securities (Month/Day/Year) (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)			6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)
Restricted Share Units	(2)	02/28/2023		M			18,430	(3)	(3)	Ordinary Shares (1)	18,430	\$ 0	18,430	D
Restricted Share Units	(2)	02/28/2023		M			44,953	(4)	(4)	Ordinary Shares (1)	44,953	\$ 0	0	D

Explanation of Responses:

(1) The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

(2) Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

(3) Restricted share units were granted on February 28, 2020 with 18,430 vested on each of February 28, 2021, February 28, 2022, February 28, 2023 and 18,430 vesting on February 28, 2024.

(4) Restricted share units were granted on February 7, 2023 pursuant to the satisfaction of performance criteria and vested on February 28, 2023.

/s/ Dov Bergwerk as attorney-in-fact for Eliyahu Sharon Kalif	03/02/2023
------------------------------------------------------------------	------------

**Signature of Reporting Person Date

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.